1135205-94-5
1135205-94-5
Chemical Structure
AWL-II-38.3
- CAS No.: 1135205-94-5
- Formula:C23H18F3N5O3
- Molecular Weight:469.42
IUPAC Name: N-(2-methyl-5-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamido)phenyl)isoxazole-5-carboxamide
InChIKey: IYUFHBXMTTXZBE-UHFFFAOYSA-N
SMILES: O=C(C1=CC=NO1)NC2=CC(NC(C3=CC(C(F)(F)F)=CC(N4C=NC(C)=C4)=C3)=O)=CC=C2C
Biological Activity: AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf[1][2][1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AWL-II-38.3 | 99.68% | AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yongmun Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4467-70. [Content Brief]
- [2]. Efrat Mashiach-Farkash, et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget. 2012 Jun;3(6):629-39. [Content Brief]
